GLP-1 receptor agonists today

Diabetes Research and Clinical Practice

Volumn 93, Issue 3, 2011, Pages 317-327

  Marre, Michel ^a   Penfornis, Alfred ^b  

^a BICHAT HOSPITAL   (France)

^b Bâtiment Socrate   (France)

Author keywords

Exenatide; GLP 1 receptor agonist; Liraglutide; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; ELIGEN; EXENDIN 4; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; NN 9068; NN 9924; ORAL ANTIDIABETIC AGENT; PC DAC; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 80052755057     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.01.004     Document Type: Review

References (87)

1. International Diabetes Federation The diabetes atlas 2009, 4th ed.
2. Scheen A.J., Lefebvre P.J. Insulin action in man. Diabetes Metab 1996, 22:105-110.
3. Aronoff S.L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004, 17:183-189.
4. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
5. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
6. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
7. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
8. Ziemer D.C., Miller C.D., Rhee M.K., Doyle J.P., Watkins C., Cook C.B., et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005, 31:564-571.
9. Nicolucci A., Rossi M.C. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008, 79:184-191.
10. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
11. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
12. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
13. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
14. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
15. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113:546-593.
16. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498.
17. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
18. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
19. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
20. Meier J.J., Gallwitz B., Salmen S., Goetze O., Holst J.J., Schmidt W.E., et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:2719-2725.
21. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
22. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2263.
23. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
24. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40:205-211.
25. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
26. Novartis Galvus (vildagliptin) summary of product characteristics September 2009, Available at: http://emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/€ [accessed 26 July 2010].
27. Merck Co. Januvia (sitagliptin) summary of product characteristics November 2009, Available at: http://emc.medicines.org.uk/document.aspx?documentId=19609 [accessed 26 July 2010].
28. Bristol-Myers Squibb Onglyza (saxagliptin) summary of product characteristics October 2009, Available at: http://emc.medicines.org.uk/medicine/22315/SPC/Onglyza+5mg+film-coated+tablets/ [accessed 26 July 2010].
29. Amylin Pharmaceuticals/Eli Lilly Byetta (exenatide) summary of product characteristics 2009, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf [accessed 26 July 2010].
30. Novo Nordisk Victoza (liraglutide) summary of product characteristics July 2009, Available at: http://emc.medicines.org.uk/medicine/21986/SPC/Victoza+6+mg%2Fml+solution+for+injection+in+pre-filled+pen/ [accessed 26 July 2010].
31. Nordqvist C. Experimental diabetes drug taspoglutide late-stage trials suspended. Medical News Today September 2010, Available at: http://www.medicalnewstoday.com/articles/200893.php [accessed 13 October 2010].
32. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
33. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
34. Agersø H., Jensen L.B., Elbrønd B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
35. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2009, 49(Suppl. 1):S30-S40.
36. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin in patients with type 2 diabetes inadequately controlled on metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
37. Pratley R.E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 2008, 10:171.
38. Garber A., Henry R., Ratner R., Garcia-Hernadez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
39. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
40. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
41. Russell-Jones D., Vaag A., Schmitz O., Sethi B., Lalic N.M., Antic S., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009, 52:2046-2055.
42. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. A study of two glucagon like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
43. Nauck M.A., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009, 32:84-90.
44. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
45. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
46. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
47. Verge D., López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev 2010, 6:191-200.
48. Novo Nordisk Press release: Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial May 2010, Available at: http://www.novonordisk.com/include/asp/exe_news_attachment.pdf?sAttachmentGUID=e8174710-b1c6-4279-9850-bcb2f24368a7 [accessed on 8 October 2010].
49. Moretto T.J., Milton D.R., Ridge T.D., Macconell L.A., Okerson T., Wolka A.M., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460. Erratum in: Clin Ther, 2008;30:1937.
50. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
51. Novo Nordisk Victoza risk evaluation and mitigation strategy (REMS) January 2010, Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM202063.pdf [accessed 8 October 2010].
52. Amylin Pharmaceuticals Byetta risk evaluation and mitigation strategy (REMS) September 2009, Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM193306.pdf [accessed 8 October 2010].
53. Buse J.B., Drucker D.J., Taylor K.L., Kim T., Walsh B., Hu H., et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33:1255-1261.
54. Bergenstal R.M., Wysham C., MacConell L., Malloy J., Walsh B., Yan P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or poiglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, doi:10.1016/S0140-6736(10)60590-9.
55. Diamant M., Van Gaal L., Stranks S., Northrup J., Cao D., Taylor K., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
56. Novo Nordisk, Pipeline: semaglutide, Available at: [accessed 26 July 2010]. http://www.novonordisk.com/science/pipeline/rd_pipeline.asp%3Fshowid=7.
57. Christensen M., Knop F.K., Holst J.J., Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009, 12:503-513.
58. Tomkin G.H. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 2009, 11:579-588.
59. Seino Y., Nakajima H., Miyahara H., Kurita T., Bush M.A., Yang F., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009, 25:3049-3057.
60. Stewart M.W., Reusch J.E.B., Bush M.A., Yang F., Rosenstock J. Albiglutide, a long-acting GLP-1-receptor agonist, for the treatment of type 2 diabetes: an analysis of gastrointestinal adverse events over time. Diabetologia 2009, 52(Suppl. 1):S302.
61. Rosenstock J., Reusch J.E.B., Bush M.A., Yang F., Stewart M.W. Weekly, biweekly and monthly efficacy of albiglutide, a long-acting GLP-1-receptor agonist, in patients with type 2 diabetes receiving concomitant background metformin. Diabetologia 2009, 52(Suppl. 1):S288.
62. Novo Nordisk Press release January 2010, Available at: http://www.novonordisk.com/press/news/news.asp?sShowNewsItemGuID=acc555cc-2124-4ebf-ad6d-7f923e2e2a78&sShowLanguageCode=en-GB&sSearchText=NN9924 [accessed 26 July 2010].
63. Novo Nordisk, Pipeline: NN9068, Available at: [accessed 26 July 2010]. http://www.novonordisk.com/science/pipeline/rd_pipeline.asp%3Fshowid=17.
64. Astrup A., Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
65. American Diabetes Association Standards of medical care in diabetes-2010. Diabetes Care 2010, 33:S11-S61.
66. Haute Authorité de Santé, Traitement medicamenteux du diabete de type 2, Available at: [accessed 26 July 2010]. http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratique/Traitement-medicamenteux-du-diabete-de-type-2-recommandations-de-bonne-pratique/(language)/fre-FR.
67. Haute Authorité de Santé, Commission de la Transparence: VICTOZA 6mg/ml, solution injectable en stylo pré rempli Available at: [accessed 26 July 2010]. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/victoza_-_ct-7136.pdf.
68. Haute Authorité de Santé, Commission de la Transparence: BYETTA 5 ug/ml, 10μg/ml solution injectable en stylo pré rempli, Available at: [accessed 26 July 2010]. http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-4012_byetta.pdf.
69. National Institute for Clinical Excellence NICE clinical guideline 87 2009, Available at: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf [accessed 26 July 2010].
70. National Institute for Clinical Excellence NICE recommends liraglutide for diabetes triple therapy 2010, Available at: http://www.nice.org.uk/newsroom/news/newsdiabetes.jsp [accessed 26 July 2010].
71. Farilla L., Bulotta A., Hirshberg B., Li Calzi S., Khoury N., Noushmehr H., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
72. Rütti S., Ehses J.A., Sibler R.A., Prazak R., Rohrer L., Georgopoulos S., et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009, 150:4521-4530.
73. Tourrel C., Bailbé D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
74. Sturis J., Gotfredsen C.F., Rømer J., Rolin B., Ribel U., Brand C.L., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140:123-132.
75. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
76. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
77. National Institute for Clinical Excellence, NICE: the guidelines manual-chapter 7: assessing cost effectiveness, Available at: [accessed 26 July 2010]. http://www.nice.org.uk/media/68D/29/The_guidelines_manual_2009_-_Chapter_7_Assessing_cost_effectiveness.pdf.
78. Minshall M.E., Oglesby A.K., Wintle M.E., Valentine W.J., Roze S., Palmer A.J. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008, 11:22-33.
79. Mittendorf T., Smith-Palmer J., Timlin L., Happich M., Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes Metab 2009, 11:1068-1079.
80. Brändle M., Erny-Albrecht K.M., Goodall G., Spinas G.A., Streit P., Valentine W.J. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2009, 47:501-515.
81. Woehl A., Evans M., Tetlow A.P., McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol 2008, 7:24.
82. Sullivan S.D., Alfonso-Cristancho R., Conner C., Hammer M., Blonde L. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009, 29:1280-1288.
83. Smith I.C., Chubb B., Valentine W. Cost-effectiveness of liraglutide compared to exenatide in combination with metformin and/or sulphonylurea. Diabet Med 2010, 27(Suppl. 1). Poster 406.
84. Chubb B., Smith I., Valentine W. Liraglutide: a cost effective treatment option when added to OAD monotherapy. Diabet Med 2010, 27(Suppl. 1). Poster 409.
85. Davies M.J., Donnelly R., Barnett A.H., Jones S., Nicolay C., Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes Metab 2009, 11:1153-1162.
86. Sheffield C.A., Kane M.P., Busch R.S., Bakst G., Abelseth J.M., Hamilton R.A. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008, 14:285-292.
87. Yoon N., Cavaghan M., Brunelle R., Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009, 31:1511-1523.